Epizyme, Inc. has entered a worldwide partnership with Eisai Co. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers. Epizyme will receive $6 million upfront and is eligible to receive more than $200 million in additional R&D and sales milestones, as well as royalties. Eisai will fund all research through human proof-of-concept, at which point Epizyme can opt into a profit share and co-commercialization agr...